Bronchopulmonary Dysplasia

Respiratory
8
Pipeline Programs
7
Companies
12
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
2
1
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
Minimally invasive surfactant therapyPhase 41 trial
Active Trials
NCT02140580UnknownEst. Jun 2022
Airway Therapeutics
Airway TherapeuticsGA - Marietta
2 programs
1
1
Air-shamPhase 2/31 trial
AT-100Phase 11 trial
Active Trials
NCT04662151Completed37Est. May 2024
NCT06897839Recruiting366Est. Apr 2030
MEDIPOST
MEDIPOSTKorea - Gyeonggi
7 programs
1
1
2
PNEUMOSTEM®Phase 21 trial
Pneumostem®Phase 21 trial
Human Umbilical Cord Blood Derived-Mesenchymal Stem CellsPhase 1/21 trial
Human Umbilical Cord Blood Derived-Mesenchymal Stem CellsPhase 11 trial
PNEUMOSTEMN/A1 trial
+2 more programs
Active Trials
NCT02023788CompletedEst. Oct 2016
NCT01897987CompletedEst. Mar 2020
NCT01632475Active Not RecruitingEst. Sep 2026
+4 more trials
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
1
UNEX-42Phase 11 trial
Active Trials
NCT03857841Terminated3Est. May 2021
DynamiCure
DynamiCureMA - Waltham
1 program
Nasal swabN/A1 trial
Active Trials
NCT07411261Not Yet RecruitingEst. Mar 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
City TherapeuticsMinimally invasive surfactant therapy
Airway TherapeuticsAir-sham
MEDIPOSTPNEUMOSTEM®
MEDIPOSTPneumostem®
MEDIPOSTHuman Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Airway TherapeuticsAT-100
United TherapeuticsUNEX-42
MEDIPOSTHuman Umbilical Cord Blood Derived-Mesenchymal Stem Cells
DynamiCureNasal swab
MEDIPOSTPNEUMOSTEM
MEDIPOSTPneumostem®
MEDIPOSTPneumostem®

Clinical Trials (12)

Total enrollment: 406 patients across 12 trials

NCT02140580City TherapeuticsMinimally invasive surfactant therapy

OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP

Start: Dec 2011Est. completion: Jun 2022
Phase 4Unknown
NCT06897839Airway TherapeuticsAir-sham

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

Start: Feb 2025Est. completion: Apr 2030366 patients
Phase 2/3Recruiting
NCT04003857MEDIPOSTPNEUMOSTEM®

Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

Start: Jul 2019Est. completion: Jun 2027
Phase 2Active Not Recruiting
NCT01828957MEDIPOSTPneumostem®

Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants

Start: Apr 2013Est. completion: Aug 2015
Phase 2Completed
NCT02381366MEDIPOSTHuman Umbilical Cord Blood Derived-Mesenchymal Stem Cells

Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study

Start: Mar 2015Est. completion: May 2018
Phase 1/2Completed
NCT04662151Airway TherapeuticsAT-100

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

Start: Sep 2021Est. completion: May 202437 patients
Phase 1Completed
NCT03857841United TherapeuticsUNEX-42

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Start: Oct 2019Est. completion: May 20213 patients
Phase 1Terminated
NCT01297205MEDIPOSTHuman Umbilical Cord Blood Derived-Mesenchymal Stem Cells

Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia

Start: Dec 2010Est. completion: Dec 2011
Phase 1Completed
NCT07411261DynamiCureNasal swab

PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants

Start: Mar 2026Est. completion: Mar 2031
N/ANot Yet Recruiting
NCT02023788MEDIPOSTPNEUMOSTEM

Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study

Start: Apr 2014Est. completion: Oct 2016
N/ACompleted
NCT01897987MEDIPOSTPneumostem®

Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial

Start: Jan 2014Est. completion: Mar 2020
N/ACompleted
NCT01632475MEDIPOSTPneumostem®

Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia

Start: Sep 2011Est. completion: Sep 2026
N/AActive Not Recruiting

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 406 patients
7 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)